More insights.
More insights.
Subscribe to our newsletter.
Deep dives into design thinking, creative process, and the intersection of business and aesthetics.
Demand Wave, Missing Beds
By 2050 the ageing curve becomes a wall: one in six people will be 65+, making longevity the largest structural driver of care demand in modern history. Dementia rises with it: cases are forecast to jump from ~57 million in 2019 to ~153 million by 2050—nearly tripling within a single generation worldwide.
In Europe and the US, demand outpaces capacity in beds, staff, and budgets. OECD and EU analyses show long-term care labour shortages and rising age-related costs through 2070. Systems struggle to recruit, retain, and fund the hours of care that demographics now require at scale, safely, and with quality.
The result is hidden rationing: long queues, delayed discharge, and families filling the gap as unpaid caregivers. UK data show hospital occupancy above safe thresholds while social care slots lag; across OECD countries, LTC workforce share must rise by ~30% this decade simply to hold ground sustainably.
Asia is not immune. ASEAN and ADB studies warn older populations are expanding faster than formal care systems. Thailand, Singapore, and Malaysia lead the region, yet specialist memory capacity remains thin relative to need—an opening for purpose-built, measurable dementia platforms to scale rapidly.
Every 3.2 seconds someone in the world develops dementia. That cadence reframes the investor lens: demand is demography, not sentiment. In a sector where churn is driven by distress—night episodes, crisis transfers—solutions that reliably deliver calmer days earn trust and durable referral velocity.
The Cost–Quality Frontier
Western long-term care costs are rising fast. In the US, the annual median cost of a nursing-home private room reached about $127,750 in 2024, with assisted living near $70,800—and occupancy climbing. In the UK, nursing care averages roughly £1,545 per week, pushing families toward alternatives. For investors, these unit trends make status-quo capacity a costly proposition—and innovation urgent.
Ageing costs also pressure public budgets. The EU’s 2024 Ageing Report projects higher age-related spending through 2070, while the European Central Bank flags fiscal risks. Meanwhile the OECD documents persistent LTC labour scarcity. This is not cyclical noise; it is a structural funding and staffing gap.
Thailand’s private medical sector offers a credible release valve: large JCI-accredited clusters, fast diagnostics, and procedure savings often cited at 50–70% versus US or UK comparators. For older adults, that means access plus value; for insurers and employers, it means predictable episode costs and flow.
Quality is visible, not theoretical. Bumrungrad alone treats roughly 1.1 million patients annually, about half international, with subspecialists, robotic platforms, and hotel-grade recovery suites. Scale and processes built for international pathways translate into fewer surprises for customers and payers.
For dementia specifically, cost outcomes hinge on behaviour, not just beds. Programmes that reduce night episodes and sedative days lower transfers, ER visits, and total cost of care. When those gains are measured—on agitation scales, medication days, and transfers—they become contracts, not anecdotes.
Nayuran as a System, Not a Site
Nayuran converts the frontier into an operating system: ritual-based dementia care embedded in architecture, Motion and Life Studios, and a digital family layer that makes distance small. The Institute trains teams; licensing exports the Method; dashboards track agitation, medication days, nights, and transfers.
Because our levers target behaviour, not just occupancy, we aim to lower crisis events that drive cost. Measurable calm increases stay length and loyalty; fewer transfers protect payer budgets. Families see weekly Memory Capsules; clinicians see trendlines; managers see rosters that breathe instead of burn.
The Thailand setting compounds value. Top-tier private hospitals handle diagnostics and surgery fast; coastal microclimates support daily movement; living costs remain favourable. For outcomes-based contracts, this means stable pathways, predictable unit economics, and consistent experience in practice.
Scaling is disciplined, not capex-heavy. A partner site licenses the Method, trains through the Institute, and activates the Family Peace layer; oversight runs through outcome dashboards. The replicable playbook yields defensible differentiation and a multi-stream model—care, licensing, training, and SaaS.
The result for investors and insurers is a rare alignment: rising demand, lower structural cost base, and auditable non-pharma outcomes. In a world where a new dementia case appears every few seconds, platforms that reliably deliver calmer days will capture trust, referrals, and durable, compounding growth.
"Demography guarantees demand. The winners will turn calmer days and fewer transfers into auditable KPIs. That’s how non-pharma dementia care moves from promise to contracts—and why Nayuran is built as a system, not a site."
— Laurent Weber, Founder, Nayuran
Where Capital Meets Care
The dementia curve won’t wait. Investors need platforms that scale outcomes, not just buildings. With Thailand’s quality backbone and Nayuran’s measurable calm—fewer sedative days, fewer transfers, engaged families—the economics align with dignity, creating growth that lasts. In that alignment, trust compounds—and so do returns.
Demand Wave, Missing Beds
By 2050 the ageing curve becomes a wall: one in six people will be 65+, making longevity the largest structural driver of care demand in modern history. Dementia rises with it: cases are forecast to jump from ~57 million in 2019 to ~153 million by 2050—nearly tripling within a single generation worldwide.
In Europe and the US, demand outpaces capacity in beds, staff, and budgets. OECD and EU analyses show long-term care labour shortages and rising age-related costs through 2070. Systems struggle to recruit, retain, and fund the hours of care that demographics now require at scale, safely, and with quality.
The result is hidden rationing: long queues, delayed discharge, and families filling the gap as unpaid caregivers. UK data show hospital occupancy above safe thresholds while social care slots lag; across OECD countries, LTC workforce share must rise by ~30% this decade simply to hold ground sustainably.
Asia is not immune. ASEAN and ADB studies warn older populations are expanding faster than formal care systems. Thailand, Singapore, and Malaysia lead the region, yet specialist memory capacity remains thin relative to need—an opening for purpose-built, measurable dementia platforms to scale rapidly.
Every 3.2 seconds someone in the world develops dementia. That cadence reframes the investor lens: demand is demography, not sentiment. In a sector where churn is driven by distress—night episodes, crisis transfers—solutions that reliably deliver calmer days earn trust and durable referral velocity.
The Cost–Quality Frontier
Western long-term care costs are rising fast. In the US, the annual median cost of a nursing-home private room reached about $127,750 in 2024, with assisted living near $70,800—and occupancy climbing. In the UK, nursing care averages roughly £1,545 per week, pushing families toward alternatives. For investors, these unit trends make status-quo capacity a costly proposition—and innovation urgent.
Ageing costs also pressure public budgets. The EU’s 2024 Ageing Report projects higher age-related spending through 2070, while the European Central Bank flags fiscal risks. Meanwhile the OECD documents persistent LTC labour scarcity. This is not cyclical noise; it is a structural funding and staffing gap.
Thailand’s private medical sector offers a credible release valve: large JCI-accredited clusters, fast diagnostics, and procedure savings often cited at 50–70% versus US or UK comparators. For older adults, that means access plus value; for insurers and employers, it means predictable episode costs and flow.
Quality is visible, not theoretical. Bumrungrad alone treats roughly 1.1 million patients annually, about half international, with subspecialists, robotic platforms, and hotel-grade recovery suites. Scale and processes built for international pathways translate into fewer surprises for customers and payers.
For dementia specifically, cost outcomes hinge on behaviour, not just beds. Programmes that reduce night episodes and sedative days lower transfers, ER visits, and total cost of care. When those gains are measured—on agitation scales, medication days, and transfers—they become contracts, not anecdotes.
Nayuran as a System, Not a Site
Nayuran converts the frontier into an operating system: ritual-based dementia care embedded in architecture, Motion and Life Studios, and a digital family layer that makes distance small. The Institute trains teams; licensing exports the Method; dashboards track agitation, medication days, nights, and transfers.
Because our levers target behaviour, not just occupancy, we aim to lower crisis events that drive cost. Measurable calm increases stay length and loyalty; fewer transfers protect payer budgets. Families see weekly Memory Capsules; clinicians see trendlines; managers see rosters that breathe instead of burn.
The Thailand setting compounds value. Top-tier private hospitals handle diagnostics and surgery fast; coastal microclimates support daily movement; living costs remain favourable. For outcomes-based contracts, this means stable pathways, predictable unit economics, and consistent experience in practice.
Scaling is disciplined, not capex-heavy. A partner site licenses the Method, trains through the Institute, and activates the Family Peace layer; oversight runs through outcome dashboards. The replicable playbook yields defensible differentiation and a multi-stream model—care, licensing, training, and SaaS.
The result for investors and insurers is a rare alignment: rising demand, lower structural cost base, and auditable non-pharma outcomes. In a world where a new dementia case appears every few seconds, platforms that reliably deliver calmer days will capture trust, referrals, and durable, compounding growth.
"Demography guarantees demand. The winners will turn calmer days and fewer transfers into auditable KPIs. That’s how non-pharma dementia care moves from promise to contracts—and why Nayuran is built as a system, not a site."
— Laurent Weber, Founder, Nayuran
Where Capital Meets Care
The dementia curve won’t wait. Investors need platforms that scale outcomes, not just buildings. With Thailand’s quality backbone and Nayuran’s measurable calm—fewer sedative days, fewer transfers, engaged families—the economics align with dignity, creating growth that lasts. In that alignment, trust compounds—and so do returns.
Demand Wave, Missing Beds
By 2050 the ageing curve becomes a wall: one in six people will be 65+, making longevity the largest structural driver of care demand in modern history. Dementia rises with it: cases are forecast to jump from ~57 million in 2019 to ~153 million by 2050—nearly tripling within a single generation worldwide.
In Europe and the US, demand outpaces capacity in beds, staff, and budgets. OECD and EU analyses show long-term care labour shortages and rising age-related costs through 2070. Systems struggle to recruit, retain, and fund the hours of care that demographics now require at scale, safely, and with quality.
The result is hidden rationing: long queues, delayed discharge, and families filling the gap as unpaid caregivers. UK data show hospital occupancy above safe thresholds while social care slots lag; across OECD countries, LTC workforce share must rise by ~30% this decade simply to hold ground sustainably.
Asia is not immune. ASEAN and ADB studies warn older populations are expanding faster than formal care systems. Thailand, Singapore, and Malaysia lead the region, yet specialist memory capacity remains thin relative to need—an opening for purpose-built, measurable dementia platforms to scale rapidly.
Every 3.2 seconds someone in the world develops dementia. That cadence reframes the investor lens: demand is demography, not sentiment. In a sector where churn is driven by distress—night episodes, crisis transfers—solutions that reliably deliver calmer days earn trust and durable referral velocity.
The Cost–Quality Frontier
Western long-term care costs are rising fast. In the US, the annual median cost of a nursing-home private room reached about $127,750 in 2024, with assisted living near $70,800—and occupancy climbing. In the UK, nursing care averages roughly £1,545 per week, pushing families toward alternatives. For investors, these unit trends make status-quo capacity a costly proposition—and innovation urgent.
Ageing costs also pressure public budgets. The EU’s 2024 Ageing Report projects higher age-related spending through 2070, while the European Central Bank flags fiscal risks. Meanwhile the OECD documents persistent LTC labour scarcity. This is not cyclical noise; it is a structural funding and staffing gap.
Thailand’s private medical sector offers a credible release valve: large JCI-accredited clusters, fast diagnostics, and procedure savings often cited at 50–70% versus US or UK comparators. For older adults, that means access plus value; for insurers and employers, it means predictable episode costs and flow.
Quality is visible, not theoretical. Bumrungrad alone treats roughly 1.1 million patients annually, about half international, with subspecialists, robotic platforms, and hotel-grade recovery suites. Scale and processes built for international pathways translate into fewer surprises for customers and payers.
For dementia specifically, cost outcomes hinge on behaviour, not just beds. Programmes that reduce night episodes and sedative days lower transfers, ER visits, and total cost of care. When those gains are measured—on agitation scales, medication days, and transfers—they become contracts, not anecdotes.
Nayuran as a System, Not a Site
Nayuran converts the frontier into an operating system: ritual-based dementia care embedded in architecture, Motion and Life Studios, and a digital family layer that makes distance small. The Institute trains teams; licensing exports the Method; dashboards track agitation, medication days, nights, and transfers.
Because our levers target behaviour, not just occupancy, we aim to lower crisis events that drive cost. Measurable calm increases stay length and loyalty; fewer transfers protect payer budgets. Families see weekly Memory Capsules; clinicians see trendlines; managers see rosters that breathe instead of burn.
The Thailand setting compounds value. Top-tier private hospitals handle diagnostics and surgery fast; coastal microclimates support daily movement; living costs remain favourable. For outcomes-based contracts, this means stable pathways, predictable unit economics, and consistent experience in practice.
Scaling is disciplined, not capex-heavy. A partner site licenses the Method, trains through the Institute, and activates the Family Peace layer; oversight runs through outcome dashboards. The replicable playbook yields defensible differentiation and a multi-stream model—care, licensing, training, and SaaS.
The result for investors and insurers is a rare alignment: rising demand, lower structural cost base, and auditable non-pharma outcomes. In a world where a new dementia case appears every few seconds, platforms that reliably deliver calmer days will capture trust, referrals, and durable, compounding growth.
"Demography guarantees demand. The winners will turn calmer days and fewer transfers into auditable KPIs. That’s how non-pharma dementia care moves from promise to contracts—and why Nayuran is built as a system, not a site."
— Laurent Weber, Founder, Nayuran
Where Capital Meets Care
The dementia curve won’t wait. Investors need platforms that scale outcomes, not just buildings. With Thailand’s quality backbone and Nayuran’s measurable calm—fewer sedative days, fewer transfers, engaged families—the economics align with dignity, creating growth that lasts. In that alignment, trust compounds—and so do returns.